Materials and methods for reduction of protein tau and treatment of neurodegenerative diseases
US8940945B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jul 25, 2011 |
| Grant date | Jan 27, 2015 |
| Priority date | — |
| Expiry date | Jul 25, 2031 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07C2603/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The subject invention provides a myricanol compound that is in predominant form of (+)-αR,11S-myricanol as compared to (−)-αS,11R-myricanol. In one embodiment, the (+)-αR,11S-myricanol is isolated from Myrica cerifera, and is in about 86% enantiomeric excess of (−)-αS,11R-myricanol. The subject invention also pertains to therapeutic compositions and methods for treatment of neurodegenerative diseases, in particular, neurodegenerative diseases associated with abnormal accumulation of protein tau. Specifically exemplified herein is the therapeutic use of myricanol and myricanone isolated from root barks of Myrica species. Also provided are methods for preparing extracts of the subject invention from Myrica species.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.